Search
Ginsenoside Rg1
go.drugbank.com/drugs/DB06750ExperimentalNutraceuticalGinsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy.
Isaralgagene civaparvovec
go.drugbank.com/drugs/DB16808InvestigationalIsaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.
ADP-A2M4CD8
go.drugbank.com/drugs/DB25733InvestigationalADP-A2M4CD8 is under investigation in clinical trial NCT04044859 (ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS
Difloxacin
go.drugbank.com/drugs/DB11511ExperimentalVet approvedAs an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.
Puromycin
go.drugbank.com/drugs/DB08437ExperimentalIt is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
Palucorcel
go.drugbank.com/drugs/DB17955InvestigationalDeveloped by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.
Propidium
go.drugbank.com/drugs/DB02166ExperimentalQuaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Alobresib
go.drugbank.com/drugs/DB14970InvestigationalAlobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants